HomeBUSINESS
BUSINESS

Eisai, Merck to Expand Enrollment of Keytruda Combination Trials with Lenvima/Halaven
(Sep.6.2017)

Eisai said on September 6 that it has agreed with Merck & Co. to boost the target number of patients to be enrolled in their PIb/II combination therapy trials pairing the US giant’s PD-1 inhibitor Keytruda (pembrolizumab) with Lenvima (lenvatinib) and Halaven (eribulin), respectively ...
(LOG IN FOR FULL STORY)

News Calendar